GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kintor Pharmaceutical Ltd (HKSE:09939) » Definitions » PB Ratio

Kintor Pharmaceutical (HKSE:09939) PB Ratio : 1.14 (As of May. 26, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Kintor Pharmaceutical PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2024-05-26), Kintor Pharmaceutical's share price is HK$1.28. Kintor Pharmaceutical's Book Value per Share for the quarter that ended in Dec. 2023 was HK$1.12. Hence, Kintor Pharmaceutical's PB Ratio of today is 1.14.

The historical rank and industry rank for Kintor Pharmaceutical's PB Ratio or its related term are showing as below:

HKSE:09939' s PB Ratio Range Over the Past 10 Years
Min: 0.16   Med: 2.66   Max: 101.74
Current: 1.14

During the past 6 years, Kintor Pharmaceutical's highest PB Ratio was 101.74. The lowest was 0.16. And the median was 2.66.

HKSE:09939's PB Ratio is ranked better than
80.26% of 1312 companies
in the Biotechnology industry
Industry Median: 2.5 vs HKSE:09939: 1.14

During the past 12 months, Kintor Pharmaceutical's average Book Value Per Share Growth Rate was -70.00% per year. During the past 3 years, the average Book Value Per Share Growth Rate was -38.60% per year. During the past 5 years, the average Book Value Per Share Growth Rate was 17.20% per year.

During the past 6 years, the highest 3-Year average Book Value Per Share Growth Rate of Kintor Pharmaceutical was 89.00% per year. The lowest was -38.60% per year. And the median was 49.60% per year.

Back to Basics: PB Ratio


Kintor Pharmaceutical PB Ratio Historical Data

The historical data trend for Kintor Pharmaceutical's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kintor Pharmaceutical PB Ratio Chart

Kintor Pharmaceutical Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
PB Ratio
Get a 7-Day Free Trial - 2.16 2.35 2.64 1.46

Kintor Pharmaceutical Semi-Annual Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 2.35 5.21 2.64 1.11 1.46

Competitive Comparison of Kintor Pharmaceutical's PB Ratio

For the Biotechnology subindustry, Kintor Pharmaceutical's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kintor Pharmaceutical's PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Kintor Pharmaceutical's PB Ratio distribution charts can be found below:

* The bar in red indicates where Kintor Pharmaceutical's PB Ratio falls into.



Kintor Pharmaceutical PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

Kintor Pharmaceutical's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Dec. 2023)
=1.28/1.12
=1.14

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.


Kintor Pharmaceutical  (HKSE:09939) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


Kintor Pharmaceutical PB Ratio Related Terms

Thank you for viewing the detailed overview of Kintor Pharmaceutical's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Kintor Pharmaceutical (HKSE:09939) Business Description

Traded in Other Exchanges
Address
No. 20 Songbei Road, Suzhou Industrial Park, Jiangsu, Suzhou, CHN, 215123
Kintor Pharmaceutical Ltd is a clinical-stage novel drug developer in China focused on the proprietary R&D of drugs for cancers and other AR-related diseases. The company's drug candidate, Pruxelutamide, is a drug undergoing phase III clinical trials in China and phase III clinical trials in the United States for mCRPC as well as clinical trials for breast cancer. Its pipeline of seven drug candidates includes Pruxelutamide (GT0918), Pyrilutamide (KX-826), ALK-1 (GT90001), Detorsertib (GT0486), Hedgehog/SMO Inhibitor (GT1708F), PD-L1/TGF-ß (GT90008), and AR-PROTAC Compound (GT20029). It operates in a single segment focusing on the research and development of medical products.
Executives
Tong Youzhi 2101 Beneficial owner
Kt International Investment Limited 2101 Beneficial owner
Guo Chuangxing 2201 Interest of corporation controlled by you
Kg Development Limited 2101 Beneficial owner
Nomura Holdings, Inc. 2201 Interest of corporation controlled by you
Tong Youzhi 2201 Interest of corporation controlled by you
Zhu Hai Ge Li Jin Rong Tou Zi Guan Li You Xian Gong Si 2101 Beneficial owner
Zhu Hai Ge Li Ji Tuan You Xian Gong Si 2201 Interest of corporation controlled by you
Sovereign Fiduciaries (hong Kong) Limited
Kiya Company Limited
Lian Xiang Kong Gu Gu Fen You Xian Gong Si 2201 Interest of corporation controlled by you
Nan Ming You Xian Gong Si 2201 Interest of corporation controlled by you
Shi Xian You Xian Gong Si 2101 Beneficial owner

Kintor Pharmaceutical (HKSE:09939) Headlines

No Headlines